Focused On-demand Library for GAS2-like protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NHY3

UPID:

GA2L2_HUMAN

Alternative names:

GAS2-related protein on chromosome 17; Growth arrest-specific protein 2-like 2

Alternative UPACC:

Q8NHY3; Q8NHY4

Background:

GAS2-like protein 2, also known as GAS2-related protein on chromosome 17, plays a crucial role in cellular structure and function. It is involved in the cross-linking of microtubules and microfilaments, regulating microtubule dynamics and stability. This protein enhances ADORA2-mediated adenylyl cyclase activation and is pivotal in regulating ciliary orientation and performance in airway cells.

Therapeutic significance:

GAS2-like protein 2 is linked to Ciliary dyskinesia, primary, 41, a genetic disorder characterized by respiratory infections and abnormalities of motile cilia. Understanding the role of GAS2-like protein 2 could open doors to potential therapeutic strategies for treating this condition.